drugset / Trial / NCT05557838
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Timeline
- Start
- 2023-02-15
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |